NCT02201043View on ClinicalTrials.gov

Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis

PHASE2CompletedINTERVENTIONAL
Enrollment

197

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Ankylosing Spondylitis
Interventions
DRUG

Thalidomide 150mg

DRUG

Thalidomide 100mg

DRUG

Placebo

Trial Locations (9)

100853

The General Hospital of People's Liberation Army, Beijing

200032

Zhongshan Hospital Fudan University, Shanghai

200052

Shanghai Guanghua Hospital, Shanghai

200433

Changhai Hospital, Shanghai

233004

The First Affiliated Hospital of Bengbu Medical College, Bengbu

610041

West China Hospital of Sichuan University, Chengdu

610072

Sichuan Provincial People's Hospital, Chengdu

710032

Xijing Hospital, XiAn

830001

The Xinjiang Uygur Autonomous Region people's Hospital, Ürümqi

All Listed Sponsors
lead

Shanghai Pharmaceuticals Holding Co., Ltd

INDUSTRY

NCT02201043 - Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis | Biotech Hunter | Biotech Hunter